Tumor tissue derived extracellular vesicles promote diabetic wound healing
Quick Facts
- Publication title: Tumor tissue derived extracellular vesicles promote diabetic wound healing
- Journal: J DIABETES COMPLICAT
- Year: 2023
- DOI: 10.2147/IJN.S522994
- PMID/PMCID: 40837696; PMC12363982
Research overview
This study aims to explore the effects of TNF-α-preconditioned ADSCs-exos (T-exos) on restoring DC function and accelerating wound healing in T2DM. By synergistically dampening inflammation and enhancing tissue repair, T-exos exhibit significant potential for clinical application in T2DM wounds.
Key findings
Under high glucose conditions, T-exos suppressed DC activation, as evidenced by reduced CD80/CD86 expression and NLRP3 inflammasome activity.
In vivo studies showed that T-exos promoted wound closure in T2DM mice, enhancing collagen deposition, angiogenesis, and fibroblast proliferation.
Mechanistically, TNF-α enriched miR-146a-5p in exosomes, which targeted TXNIP to inhibit NLRP3 inflammasome activation in DCs.
Knockdown of miR-146a-5p abolished these effects in vitro and the therapeutic effect of T-exos on wound healing in vivo.
Study design
T-exos were isolated from ADSCs pretreated with TNF-α.
The regulatory effects of T-exos on DC immune responses under high glucose conditions were assessed.
Subsequently, the roles of DCs treated with T-exos in diabetic wound healing were evaluated.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Tissue EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Tumor tissue derived extracellular vesicles promote diabetic wound healing Journal of diabetes and its complications. 2023. DOI: 10.2147/IJN.S522994. PMID/PMCID: 40837696; PMC12363982.